PureTech’s Karuna Gets Another $68m For Re-engineered Lilly CNS Candidate

 
• By Eleanor Malone

Karuna Therapeutics plans to expand its development program for lead candidate KarXT beyond its current Phase II trial in schizophrenia. The series B financing follows a $42m series A in 2018.

Phoenix
Can xanomeline rise from the ashes? • Source: Shutterstock

More from Financing

More from Business